Caballería J, Baraona E, Deulofeu R, Hernández-Muñoz R, Rodés J, Lieber C S
Alcohol Research and Treatment Center, Bronx Veterans Affairs Medical Center, New York, New York 10468.
Dig Dis Sci. 1991 Dec;36(12):1673-9. doi: 10.1007/BF01296608.
Inhibition of gastric alcohol dehydrogenase (ADH) activity by cimetidine results in elevated blood levels of ethanol after moderate consumption. To search for alternative H2-blockers lacking such an effect, we compared cimetidine, ranitidine, nizatidine, and famotidine. They inhibited rat gastric ADH noncompetitively, with a Ki for ethanol oxidation of 0.68 mM for cimetidine, 0.5 mM for ranitidine, 1 mM for nizatidine, and 4.5 mM for famotidine. These concentrations are higher than therapeutic plasma levels, but intracellular concentrations in the gastric mucosa (assessed with [3H]cimetidine and [14C]famotidine) were at least 10- and 2-fold greater than in the blood, respectively. These results suggests that, given at therapeutic doses in vivo, the degree of inhibition by cimetidine and ranitidine should be significant and comparable, that by nizatidine should be smaller, and that by famotidine should be negligible. These drugs also exerted either mixed or competitive inhibition of rat hepatic ADH, but the effects of cimetidine and famotidine were observed at concentrations unlikely to occur in vivo. Thus, in alcoholics and in social drinkers who require treatment with H2-receptor antagonists, famotidine might be preferable to the other H2 blockers tested.
西咪替丁对胃乙醇脱氢酶(ADH)活性的抑制作用会导致适度饮酒后血液中乙醇水平升高。为了寻找不存在这种效应的替代H2受体阻滞剂,我们对西咪替丁、雷尼替丁、尼扎替丁和法莫替丁进行了比较。它们对大鼠胃ADH的抑制作用为非竞争性,对于乙醇氧化反应,西咪替丁的Ki为0.68 mM,雷尼替丁为0.5 mM,尼扎替丁为1 mM,法莫替丁为4.5 mM。这些浓度高于治疗性血浆水平,但胃黏膜中的细胞内浓度(用[3H]西咪替丁和[14C]法莫替丁评估)分别至少比血液中的浓度高10倍和2倍。这些结果表明,在体内给予治疗剂量时,西咪替丁和雷尼替丁的抑制程度应显著且相当,尼扎替丁的抑制程度较小,法莫替丁的抑制程度可忽略不计。这些药物对大鼠肝ADH也表现出混合性或竞争性抑制作用,但西咪替丁和法莫替丁的作用是在体内不太可能出现的浓度下观察到的。因此,对于需要用H2受体拮抗剂治疗的酗酒者和社交饮酒者,法莫替丁可能比其他测试的H2阻滞剂更可取。